Sermorelin vs Tesamorelin
Both are categorized under GH release in our directory—here is how they differ in name, use, and label context.
Both are categorized under GH release in our directory—here is how they differ in name, use, and label context.
PubMed paper counts, ClinicalTrials.gov listings, and regulatory context—aggregated from public databases.
GH release
A GHRH analog that prompts the pituitary to release growth hormone—often stacked with GHRP peptides in clinic and research conversations.
Sermorelin mimics the first 29 amino acids of growth-hormone-releasing hormone. It stimulates pulsatile GH release rather than supplying GH directly. It was FDA-approved as a diagnostic (Geref) but is widely discussed of…
GH release
An FDA-approved GHRH analog for HIV-associated visceral fat—one of the few legitimate prescription GH-axis peptides in the U.S.
Tesamorelin is a stabilized GHRH analog that increases GH and IGF-1. It is approved (as Egrifta) to reduce excess abdominal fat in HIV lipodystrophy. Bodybuilders sometimes discuss it for fat redistribution, but that is …
Both are categorized under GH release in our directory—here is how they differ in name, use, and label context. Sermorelin is categorized as GH release; Tesamorelin as GH release. Sermorelin: A GHRH analog that prompts the pituitary to release growth hormone—often stacked with GHRP peptides in clinic and research conversations. Tesamorelin: An FDA-approved GHRH analog for HIV-associated visceral fat—one of the few legitimate prescription GH-axis peptides in the U.S.
No. They are different molecules with distinct names on labels and in research databases. Always match the full INCI or drug name—not a nickname on the front of the package.
Neither page is medical or anti-doping advice. Research peptides discussed in fitness communities may be prohibited in tested sport or unavailable as OTC supplements. Verify WADA lists and talk to a clinician.